CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2008 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2008, management expects net sales to be in the range of $140 to $142 million and per share diluted earnings to be between $0.72 and $0.75. The per share estimates assume an increase in average shares outstanding from approximately 40.7 million at fiscal 2007 year end to 41 million at fiscal 2008 year end. Net income is expected to increase between 20% and 25% from fiscal 2007 to fiscal 2008. Importantly, this increase excludes the impact of tax benefits of $2.4 million, or $0.06 per diluted share, recognized in fiscal 2007 which are not expected to recur. The sales and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2007 or 2008.
